It has been shown that SGLT2 inhibitors combined with an angiotensin-converting enzyme inhibitor upregulate the renin–angiotensin system effect in nephropathy, therefore suggesting that blood pressure changes may be influenced by SGLT2 inhibitors (7, 8). This evidence concerns the gene SLC5A2 and Nephropathy.